Skip to main content
Figure 2 | BMC Urology

Figure 2

From: Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain

Figure 2

Secondary analysis performed using actual prices for antimuscarinic drugs. Reductions in the costs of antimuscarinic drugs were assumed for this analysis; other components of healthcare costs were kept constant. Health costs included primary (outpatient) and specialized care. Data were adjusted by location, age, sex, medication possession ratio, time since diagnosis and Charlson comorbidity index.

Back to article page

BMC Urology

ISSN: 1471-2490

Contact us